Old HIV drug gets new shot at fighting stubborn cancers

This early-stage trial is testing whether adding lamivudine, a drug typically used for HIV, can help restart the effectiveness of immunotherapy in patients with advanced solid tumors that have stopped responding. The study will enroll 6-24 patients at Mount Sinai to first check safety and then see if the combination can shrink tumors or slow their growth. Participants must have exhausted standard treatment options and have cancer that progressed despite previous immunotherapy.